Abstract
Current regulatory guidelines on drug-food interactions recommend an early assessment of food effect to inform clinical dosing instructions, as well as a pivotal food effect study on the to-be-marketed formulation if different from that used in earlier trials. Study waivers are currently only granted for BCS class 1 drugs. Thus, repeated food effect studies are prevalent in clinical development, with the initial evaluation conducted as early as the first-in-human studies. Information on repeated food effect studies is not common in the public domain. The goal of the work presented in this manuscript from the Food Effect PBPK IQ Working Group was to compile a dataset on these studies across pharmaceutical companies and provide recommendations on their conduct. Based on 54 studies collected, we report that most of the repeat food effect studies do not result in meaningful differences in the assessment of the food effect. Seldom changes observed were more than twofold. There was no clear relationship between the change in food effect and the formulation change, indicating that in most cases, once a compound is formulated appropriately within a specific formulation technology, the food effect is primarily driven by inherent compound properties. Representative examples of PBPK models demonstrate that following appropriate validation of the model with the initial food effect study, the models can be applied to future formulations. We recommend that repeat food effect studies should be approached on a case-by-case basis taking into account the totality of the evidence including the use of PBPK modeling.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The data used for the analysis are provided as supplementary material (Supplementary file 1).
References
Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentová K, Vertzoni M, Čepo DV, Corsetti M. The mechanisms of pharmacokinetic food-drug interactions - a perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31–59.
Tistaert C, Heimbach T, Xia B, Parrott N, Samant TS, Kesisoglou F. Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies. J Pharm Sci. 2019;108(1):592–602. https://doi.org/10.1016/j.xphs.2018.05.024.
Heimbach T, Xia B, Lin TH, He H. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J. 2013;15(1):143–58. https://doi.org/10.1208/s12248-012-9419-5.
Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E, Djebli N, Meneses-Lorente G. Physiologically based absorption modelling to explore the impact of food and gastric pH changes on the pharmacokinetics of entrectinib. AAPS J. 2020;22(4):78. https://doi.org/10.1208/s12248-020-00463-y.
Kesisoglou F. Can PBPK modeling streamline food effect assessments? J Clin Pharmacol. 2020;60(Suppl 1):S98–104. https://doi.org/10.1002/jcph.1678.
Emami RA. Predicting food effects: are we there yet? AAPS J. 2022;24(1):25. https://doi.org/10.1208/s12248-021-00674-x.
Bocci G, Oprea TI, Benet LZ. State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references. AAPS J. 2022;24(2):37.
Riedmaier AE, DeMent K, Huckle J, Bransford P, Stillhart C, Lloyd R, Alluri R, Basu S, Chen Y, Dhamankar V, Dodd S, Kulkarni P, Olivares-Morales A, Peng CC, Pepin X, Ren X, Tran T, Tistaert C, Heimbach T, Kesisoglou F, Wagner C, Parrott N. Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective. AAPS J. 2020;22(6):123. https://doi.org/10.1208/s12248-020-00508-2. (Erratum.In:AAPSJ.2020Nov26;23(1):6).
Wagner C, Kesisoglou F, Pepin XJH, Parrott N, Emami RA. Use of physiologically based pharmacokinetic modeling for predicting drug-food interactions: recommendations for improving predictive performance of low confidence food effect models. AAPS J. 2021;23(4):85.
Pepin XJH, Huckle JE, Alluri RV, Basu S, Dodd S, Parrott N, Emami RA. Understanding mechanisms of food effect and developing reliable PBPK models using a middle-out approach. AAPS J. 2021;23(1):12. https://doi.org/10.1208/s12248-020-00548-8.
Assessing the effects of food on drugs in INDs and NDAs — clinical pharmacology considerations guidance for industry, accessed on 24 Jun 2022 at https://www.fda.gov/media/121313/download.
Jain JP, Leong FJ, Chen L, Kalluri S, Koradia V, Stein DS, Wolf MC, Sunkara G, Kota J. Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers. Antimicrob Agents Chemother. 2017;61(9):e00868-e917. https://doi.org/10.1128/AAC.00868-17.
Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K, Wagner JA. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;68(4):535–45. https://doi.org/10.1111/j.1365-2125.2009.03465.x.
McKelvey CA, Kesisoglou F. Enabling an HCV treatment revolution and the frontiers of solid solution formulation. J Pharm Sci. 2019;108(1):50–7.
Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review, accessed at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000ClinPharmR.pdf. Accessed 25 Mar 2023
Stillhart C, Parrott NJ, Lindenberg M, Chalus P, Bentley D, Szepes A. Characterising drug release from immediate-release formulations of a poorly soluble compound, basmisanil, through absorption modelling and dissolution testing. AAPS J. 2017;19(3):827–36. https://doi.org/10.1208/s12248-017-0060-1.
Gajewska M, Blumenstein L, Kourentas A, Mueller-Zsigmondy M, Lorenzo S, Sinn A, Velinova M, Heimbach T. Physiologically based pharmacokinetic modeling of oral absorption, ph, and food effect in healthy volunteers to drive alpelisib formulation selection. AAPS J. 2020;22(6):134.
Pepin XJH, Hammarberg M, Mattinson A, Moir A. Physiologically based biopharmaceutics model for selumetinib food effect investigation and capsule dissolution safe space - part I: adults. Pharm Res. 2022. https://doi.org/10.1007/s11095-022-03339-2.
Pepin XJ, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CE. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. Mol Pharm. 2016;13(9):3256–69.
Pepin XJH, Sanderson NJ, Blanazs A, Grover S, Ingallinera TG, Mann JC. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. Eur J Pharm Biopharm. 2019;142:421–34.
Author information
Authors and Affiliations
Contributions
Data gathering, data analysis, and data discussion at WG meetings: All authors
Manuscript compilation and primary authoring: Filippos Kesisoglou, Phil Bransford, Christian Wagner, Tycho Heimbach, Neil Parrott, Summit Basu, Pradeep Sharma, Andrea Moir
Manuscript review: All authors
Corresponding author
Ethics declarations
Conflict of Interest
The authors are employees of the respective companies listed under affiliations and may own stock or stock options in these companies.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kesisoglou, F., Basu, S., Belubbi, T. et al. Streamlining Food Effect Assessment — Are Repeated Food Effect Studies Needed? An IQ Analysis. AAPS J 25, 60 (2023). https://doi.org/10.1208/s12248-023-00822-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12248-023-00822-5